ARVN (US) share price forecast & AI signal — Arvinas, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in ARVN
Arvinas, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Arvinas, Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $6.41 |
| 2026-11-05 | $6.55 |
| 2026-11-04 | $7.42 |
| 2026-11-03 | $7.09 |
| 2026-11-02 | $7.52 |
| 2026-10-30 | $7.86 |
| 2026-10-29 | $7.90 |
ARVN FAQ
Is Arvinas, Inc (ARVN) a buy or sell this week?
The ACE Stock Bots machine-learning model rates ARVN a SELL for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for ARVN?
Every week the model scores ARVN across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.